This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original articles
Subbiah, V. et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(22)00541-1 (2022)
Drilon, A. et al. Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I/II trial. J. Clin. Oncol. https://doi.org/10.1200/JCO.22.00393 (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Romero, D. Activity of selpercatinib in RET fusion-positive cancers confirmed. Nat Rev Clin Oncol 19, 747 (2022). https://doi.org/10.1038/s41571-022-00694-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-022-00694-2